We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic stocks.

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic assessment of disease activity in IBD. By merging data science with clinical expertise,

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March ...